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Background: The COBRA-P DES stent system consists of cobalt chromium alloy with bio-absorbable siloxane sol-gel matrix coating that elutes low 
dose paclitaxel. The PLUS-ONE (PaclitaxeL Intravascular UltraSound Dose-FiNding Evaluation) study is a first-in-man trial evaluating the safety and 
performance of two doses of the COBRA-P DES.
Methods: A total of 60 lesions (53 subjects) were sequentially assigned to extremely low- (EL: 4μg/18mm; n=30; 1/40 dose of the TAXUS Liberte) 
or low-dose (L: 8μg/18mm; n=30) paclitaxel arm. Quantitative coronary angiography and intravascular ultrasound analysis were performed at 
baseline and 4-month follow-up. Volume index (VI: volume/length) was calculated for vessel (VVI), plaque (PVI), neointima (NIV), and lumen (LVI). 
Percent neointimal volume (%NIV) was calculated as (NIV/SVI)×100. Cross-sectional narrowing (CSN) was defined as neointimal area divided by 
stent area (%).
Results: There was no significant difference in reference vessel diameter between the 2 groups. At 4 months, there were no significant differences 
in angiographic late loss (0.36 ± 0.30 mm vs. 0.34 ± 0.27mm, P=0.773) and neointimal hyperplasia including %NIV (13.5 ± 9.5% vs. 10.9 ± 7.8%, 
P=0.272), or max % CSN (31.2 ± 14.4% vs. 28.6 ± 16.1%, P=0.523) between the 2 groups. The rate of late-acquired incomplete stent apposition 
(LISA) was similar between the groups (14.8 % vs. 14.3%, P=0.956). Although the volume of LISA did not differ between the 2 groups (1.0 ± 0.6 
mm3 vs. 8.6 ± 10.9 mm3, P=0.200), max area of LISA was significantly lower in EL than in L group (1.1 ± 0.3 mm2 vs. 2.5 ± 1.4 mm2, P=0.029). 
The incidence of target legion revascularization at 4 months was similar between the groups (3.3 % vs. 3.3 %). Myocardial infarction or stent 
thrombosis did not occur in either group at 4 months.
Conclusions: In these 4-month follow-up data from the first-in-man dose finding study, extremely low- and low-dose groups showed similar 
neointimal hyperplasia that was comparable to those reported in conventional paclitaxel-eluting stents. Although the rate of LISA was similar, once 
the LISA occurred, the extent of LISA appeared to be dose-dependent at the 4-month time point.
